Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21132107 | 0.83 | CYP19A1 (0.52) | CYP19A1CYP1A2CYP3A4LMNACYP11B1 | |
| SCHEMBL12040027 | 0.82 | CYP19A1 (0.55) | CYP19A1CYP1A2CYP3A4LMNACYP11B1 | |
| SCHEMBL29583584 | 0.81 | KIF11 (0.61) | CYP19A1CYP1A2CYP3A4LMNACYP11B1 | |
| SCHEMBL74389 | 0.81 | KIF11 (0.61) | CYP19A1CYP1A2CYP3A4LMNACYP11B1 | |
| SCHEMBL27996644 | 0.79 | CYP19A1 (0.57) | CYP19A1CYP1A2CYP3A4LMNACYP11B1 | |
| Boric Acid SCHEMBL29093528 | 0.78 | KIF11 (0.53) | CYP19A1CYP1A2CYP3A4LMNACYP11B1 | |
| SCHEMBL22303441 | 0.78 | CYP19A1 (0.52) | CYP19A1CYP1A2CYP3A4LMNACYP11B1 | |
| SCHEMBL16230653 | 0.78 | CYP19A1 (0.56) | CYP19A1CYP1A2CYP3A4LMNACYP11B1 | |
| SCHEMBL23059263 | 0.77 | CYP19A1 (0.55) | CYP19A1CYP1A2CYP3A4LMNACYP11B1 | |
| SCHEMBL19229667 | 0.77 | CYP19A1 (0.55) | CYP19A1CYP1A2CYP3A4LMNACYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-8569512-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120015052-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2012-01-19 | — | — | US | disclosed |
| WO-2010111060-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | CYP19A1 4351/4885CYP1A2 2564/4885CYP3A4 1303/4885 |
| US-20120015052-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | CYP19A1 4780/4885CYP1A2 3942/4885CYP3A4 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.